Skip to main content
Erschienen in: Pituitary 3/2010

01.09.2010

Thyroid cancer is the most common cancer associated with acromegaly

verfasst von: Bennur Esen Gullu, Ozlem Celik, Nurperi Gazioglu, Pinar Kadioglu

Erschienen in: Pituitary | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to screen the malignancy in an acromegalic patient group and to determine whether there was any increased risk and the incidence of malignancy and its association with disease characteristics such as duration of disease, latency in diagnosis, and GH and IGF-1 levels. One hundred-five (65 female, 40 male) patients with acromegaly followed and treated at Cerrahpasa Medical School, Endocrinology and Metabolism outpatient clinic between 1983 and 2007 were included in this study. The patients were screened with colonoscopy, mammography, and thyroid and prostate ultrasonography (US). Malignancy was detected in 16 (15%) patients. Thyroid cancer was found in 5 patients (4.7%), breast cancer in 3 (2.8%), colon cancer in 2 (1.9%), lung cancer in 2 (1.9%), cervix cancer in 1 (0.9%), myelodysplastic syndrome (MDS) in 1 (0.9%), cholangiocarcinoma in 1 (0.9%), and multiple endocrine neoplasm (MEN) type 1 in 1 patient (0.9%). Cancer was more common in the male patients (P = 0.046) and high levels of GH increased the risk of cancer development (P = 0.046). In this series, the most commonly detected cancer types were thyroid followed by breast and colon cancers. Although high levels of initial GH seemed to increase the risk of cancer development in acromegalic patients, age, gender, age at the time of diagnosis, duration of disease, and initial IGF-I levels were not associated with cancer development.
Literatur
2.
Zurück zum Zitat Ayuk J, Sheppard MC (2008) Does acromegaly enhance mortality? Rev Endocr Metab Disord 9:33–39CrossRefPubMed Ayuk J, Sheppard MC (2008) Does acromegaly enhance mortality? Rev Endocr Metab Disord 9:33–39CrossRefPubMed
3.
Zurück zum Zitat Melmed SM (2001) Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 86:2929–2934CrossRefPubMed Melmed SM (2001) Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 86:2929–2934CrossRefPubMed
4.
Zurück zum Zitat Cohen P, Clemmons DR, Rosenfeld RG (2000) Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 10:297–305CrossRefPubMed Cohen P, Clemmons DR, Rosenfeld RG (2000) Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 10:297–305CrossRefPubMed
5.
Zurück zum Zitat Renehan AG (2008) Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab 22(4):639–657CrossRefPubMed Renehan AG (2008) Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab 22(4):639–657CrossRefPubMed
6.
Zurück zum Zitat Webb Susan M, Felipe C, Wass John AH (2002) Oncological complications of excess GH in acromegaly. Pituitary 5:21–25CrossRefPubMed Webb Susan M, Felipe C, Wass John AH (2002) Oncological complications of excess GH in acromegaly. Pituitary 5:21–25CrossRefPubMed
7.
Zurück zum Zitat Jenkins P, Mukherjeet A, Shalet SM (2006) Does growth hormone cause cancer? Clin Endocrinol 64:121CrossRef Jenkins P, Mukherjeet A, Shalet SM (2006) Does growth hormone cause cancer? Clin Endocrinol 64:121CrossRef
8.
Zurück zum Zitat Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730–2734CrossRefPubMed Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730–2734CrossRefPubMed
9.
10.
Zurück zum Zitat Loeper S, Ezzat S (2008) Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord 9:41–58CrossRefPubMed Loeper S, Ezzat S (2008) Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord 9:41–58CrossRefPubMed
11.
12.
Zurück zum Zitat Barzilay J, Heatley GJ, Cushing GW (1991) Benign and malignant tumors in patients with acromegaly. Arch Intern Med 151:1629–1632CrossRefPubMed Barzilay J, Heatley GJ, Cushing GW (1991) Benign and malignant tumors in patients with acromegaly. Arch Intern Med 151:1629–1632CrossRefPubMed
13.
Zurück zum Zitat Melmed S (1996) Unwanted effects of GH excess in the adult. J Pediatr Endocrinol Metab 9:369–374PubMed Melmed S (1996) Unwanted effects of GH excess in the adult. J Pediatr Endocrinol Metab 9:369–374PubMed
14.
Zurück zum Zitat Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF (1991) Acromegaly and gastrointestinal cancer. Cancer 68:1673–1677CrossRefPubMed Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF (1991) Acromegaly and gastrointestinal cancer. Cancer 68:1673–1677CrossRefPubMed
15.
Zurück zum Zitat Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J (1998) Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 49:441–445CrossRef Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J (1998) Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 49:441–445CrossRef
16.
Zurück zum Zitat Giustina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529CrossRefPubMed Giustina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529CrossRefPubMed
17.
Zurück zum Zitat Tiryakioglu O, Kadioglu P, Caneroglu NU, Hatemi H (2003) Age dependency of serum insulin-like growth factor (IGF-1) in healthy Turkish adolescents and adults. Indian J Med Sci 57:543–548PubMed Tiryakioglu O, Kadioglu P, Caneroglu NU, Hatemi H (2003) Age dependency of serum insulin-like growth factor (IGF-1) in healthy Turkish adolescents and adults. Indian J Med Sci 57:543–548PubMed
18.
Zurück zum Zitat Mustacchi P, Shimkin MB (1957) Occurrence of cancer in acromegaly and in hypopituitarism. Cancer 10(1):100–104CrossRefPubMed Mustacchi P, Shimkin MB (1957) Occurrence of cancer in acromegaly and in hypopituitarism. Cancer 10(1):100–104CrossRefPubMed
19.
Zurück zum Zitat Klein L, Parveen G, Gavaler JS, Vanthiel DH (1982) Colonic polpys in patients with acromegaly. Ann Intern Med 97(1):27–30PubMed Klein L, Parveen G, Gavaler JS, Vanthiel DH (1982) Colonic polpys in patients with acromegaly. Ann Intern Med 97(1):27–30PubMed
20.
Zurück zum Zitat Brunner JE, Johnson CC, Zafar S, Peterson EL, Brunner JF, Mellinger RC (1990) Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol 32:65–71CrossRef Brunner JE, Johnson CC, Zafar S, Peterson EL, Brunner JF, Mellinger RC (1990) Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol 32:65–71CrossRef
21.
Zurück zum Zitat Higuchi Y, Saeki N, Iuchi T, Uchino Y, Tatsuno I, Uchida D et al (2000) Incidence of malignant tumors in patients with acromegaly. Endocr J 47(supply):57–60CrossRef Higuchi Y, Saeki N, Iuchi T, Uchino Y, Tatsuno I, Uchida D et al (2000) Incidence of malignant tumors in patients with acromegaly. Endocr J 47(supply):57–60CrossRef
22.
Zurück zum Zitat Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13:395–400CrossRefPubMed Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13:395–400CrossRefPubMed
23.
Zurück zum Zitat Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–150CrossRefPubMed Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–150CrossRefPubMed
24.
Zurück zum Zitat Tornell J, Rymo L, Isaksoon OG (1991) Induction of mammary adenocarcinomas in metallothionein promoter- human growth hormone transgenic mice. Int J Cancer 49:114–117CrossRefPubMed Tornell J, Rymo L, Isaksoon OG (1991) Induction of mammary adenocarcinomas in metallothionein promoter- human growth hormone transgenic mice. Int J Cancer 49:114–117CrossRefPubMed
25.
Zurück zum Zitat Kaulsay KK, Zhu T, Bennett W, Lee K, PE LobieE (2001) The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behaviour are mediated via the hGH receptor. Endocrinology 142:767–777CrossRefPubMed Kaulsay KK, Zhu T, Bennett W, Lee K, PE LobieE (2001) The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behaviour are mediated via the hGH receptor. Endocrinology 142:767–777CrossRefPubMed
26.
Zurück zum Zitat Zhu T, Goh EL, Graichen R, Ling L, Lobie PE (2001) Signal transduction via the growth hormone receptor. Cell Signal 13(9):599–616CrossRefPubMed Zhu T, Goh EL, Graichen R, Ling L, Lobie PE (2001) Signal transduction via the growth hormone receptor. Cell Signal 13(9):599–616CrossRefPubMed
27.
28.
Zurück zum Zitat Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19:5574–5581CrossRefPubMed Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19:5574–5581CrossRefPubMed
29.
Zurück zum Zitat Fidaner C, Eser SY, Parkin DM (2001) Incidence in Izmir in 1993–1994: first results from Izmir cancer registry. Eur J Cancer 37:83–92CrossRefPubMed Fidaner C, Eser SY, Parkin DM (2001) Incidence in Izmir in 1993–1994: first results from Izmir cancer registry. Eur J Cancer 37:83–92CrossRefPubMed
30.
Zurück zum Zitat Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, Vigneri R, Uberti EC, Pezzino V (2005) High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol 63:161–167CrossRef Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, Vigneri R, Uberti EC, Pezzino V (2005) High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol 63:161–167CrossRef
31.
Zurück zum Zitat Balkany C, Cushing GW (1995) An association between acromegaly and thyroid carcinoma. Thyroid 5:47–50CrossRefPubMed Balkany C, Cushing GW (1995) An association between acromegaly and thyroid carcinoma. Thyroid 5:47–50CrossRefPubMed
32.
Zurück zum Zitat Franceschi S, Preston Martin S, DalMaso L, Negri E, LaVecchia C, Mack WJ, McTiernan A, Kolonel L, Mark SD, Mabuchi K, Jin F, Wingren G, Galanti R, Hallquist A, Glattre E, Lund E, Levi F, Linos D, Ron E (1999) A pooled analysis of case control studies of thyroid cancer. Benign thyroid diseases. Cancer Causes Control 10:583–595CrossRefPubMed Franceschi S, Preston Martin S, DalMaso L, Negri E, LaVecchia C, Mack WJ, McTiernan A, Kolonel L, Mark SD, Mabuchi K, Jin F, Wingren G, Galanti R, Hallquist A, Glattre E, Lund E, Levi F, Linos D, Ron E (1999) A pooled analysis of case control studies of thyroid cancer. Benign thyroid diseases. Cancer Causes Control 10:583–595CrossRefPubMed
33.
Zurück zum Zitat From G, Mellemgaard A, Knudsen N, Jorgensen T, Perrild H (2000) Review of thyroid cancer cases among patients with previous benign thyroid disorders. Thyroid 10:697–700CrossRefPubMed From G, Mellemgaard A, Knudsen N, Jorgensen T, Perrild H (2000) Review of thyroid cancer cases among patients with previous benign thyroid disorders. Thyroid 10:697–700CrossRefPubMed
34.
Zurück zum Zitat Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A (2002) Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 25:240–245PubMed Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A (2002) Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 25:240–245PubMed
35.
Zurück zum Zitat Kurimoto M, Fukuda I, Hizuka N, Tkano K (2008) The prevalance of benign and malign tumors in patients with Acromegaly at a single institute. Endocr J 55:67–71CrossRefPubMed Kurimoto M, Fukuda I, Hizuka N, Tkano K (2008) The prevalance of benign and malign tumors in patients with Acromegaly at a single institute. Endocr J 55:67–71CrossRefPubMed
36.
Zurück zum Zitat Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M, Yu H (2001) Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 91:736–739CrossRefPubMed Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M, Yu H (2001) Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 91:736–739CrossRefPubMed
37.
Zurück zum Zitat Laban C, Bustin SA, Jenkins PJ (2003) The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 14:28–34CrossRefPubMed Laban C, Bustin SA, Jenkins PJ (2003) The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 14:28–34CrossRefPubMed
38.
Zurück zum Zitat Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396CrossRefPubMed Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396CrossRefPubMed
39.
Zurück zum Zitat Renehan AG, Bhaskar P, Painter JE, O’Dwyer ST, Haboubi N, Varma J, Ball SG, Shalet SM (2000) The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 85:3417–3424CrossRefPubMed Renehan AG, Bhaskar P, Painter JE, O’Dwyer ST, Haboubi N, Varma J, Ball SG, Shalet SM (2000) The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 85:3417–3424CrossRefPubMed
40.
Zurück zum Zitat Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, Wass JA, Besser M (1997) Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 47:17–22CrossRef Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, Wass JA, Besser M (1997) Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 47:17–22CrossRef
41.
Zurück zum Zitat Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115–1118PubMed Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115–1118PubMed
42.
Zurück zum Zitat Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D (1998) Insulin-like growth factor 1 and prostate cancer risk: a population based, case control study. J Natl Cancer Inst 90:911–915CrossRefPubMed Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D (1998) Insulin-like growth factor 1 and prostate cancer risk: a population based, case control study. J Natl Cancer Inst 90:911–915CrossRefPubMed
43.
Zurück zum Zitat Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB (2000) Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85:4258–4265CrossRefPubMed Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB (2000) Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85:4258–4265CrossRefPubMed
44.
Zurück zum Zitat Chan JM, Stampfer MJ, Giovanucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279:563–566CrossRefPubMed Chan JM, Stampfer MJ, Giovanucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279:563–566CrossRefPubMed
Metadaten
Titel
Thyroid cancer is the most common cancer associated with acromegaly
verfasst von
Bennur Esen Gullu
Ozlem Celik
Nurperi Gazioglu
Pinar Kadioglu
Publikationsdatum
01.09.2010
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2010
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-010-0224-9

Weitere Artikel der Ausgabe 3/2010

Pituitary 3/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.